At the news
? NEUTRALIMPACT 2/10 DEFA14A filed Apr 21, 2026 at 16:21 ET
BioMarin Pharmaceutical Inc. filed a definitive proxy statement (DEFA14A) for its annual shareholder meeting, which is routine corporate governance documentation.
- Company filed a definitive proxy statement (DEFA14A) for its annual meeting
- This is a standard regulatory filing required for shareholder meetings
- No material financial information or significant corporate actions were disclosed in this filing
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access